Pregabalin has been around for a year or so. It's a combo drug of neurontin and GABA.
LYRICA (Pregabalin) is a 3-substituted analogue of gamma-amino butyric acid (GABA) and a compound related to the antiepileptic drug gabapentin. LYRICA (Pregabalin) will be indicated as adjunctive therapy for partial seizures in epilepsy, for treatment of neuopathic pain, including diabetic peripheral neuropathy, and for treatment of generalized anxiety disorder.
FDA Approves Pfizer's Lyrica(TM) for the Treatment of the Two Most Common Forms of Neuropathic (Nerve) Pain
NEW YORK, Dec. 31 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Lyrica(TM) (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distinctly different from arthritis or musculoskeletal pain.
Developed by Pfizer, Lyrica has a newly defined mechanism of action. Lyrica will be available to physicians and patients in the near future.
NEW YORK (Reuters Health) - A new drug, Lyrica (pregabalin) is a well-tolerated, effective treatment for pain in the extremities often experienced by people with diabetes, according to a recent report. In addition to reducing the pain, the drug seems to improve sleep
Lyrica (Pregabalin) Information:
LYRICA (Pregabalin) is indicated as a treatment for peripheral neuropathic pain and as an adjunctive therapy for partial seizures in patients with epilepsy. The dose range is 150 to 600 mg per day given in either two or three divided doses. Lyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Lyrica may be taken with or without food. Neuropathic Pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.Epilepsy: Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week. Discontinuation of pregabalin: In accordance with current clinical practice, if pregabalin has to be discontinued either in neuropathic pain or epilepsy, it is recommended this should be done gradually over a minimum of 1 week. Cliniccal Experience- Neuropathic Pain: Efficacy has been shown in studies in diabetic neuropathy and post herpetic neuralgia. Efficacy has not been studied in other models of neuropathic pain. Pregabalin has been studied in 9 controlled clinical studies of up to 13 weeks with twice a day dosing (BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar. In clinical trials up to 13 weeks, a reduction in pain was seen by week 1 and was maintained throughout the treatment period. In controlled clinical trials 35% of the pregabalin treated patients and 18% of the patients on placebo had a 50% improvement in pain score. For patients not experiencing somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of patients on placebo. For patients who experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo. Clinical Experience- Epilepsy: Pregabalin has been studied in 3 controlled clinical studies of 12 week duration with either twice a day dosing (BID) or three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar. A reduction in seizure frequency was observed by Week 1. Pregabalin binds to an auxiliary subunit (a2-d protein) of voltage-gated calcium channels in the central nervous system, potently displacing [3H]-gabapentin. Speacial Precatuions Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medications. Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication. There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.
Lyrica (Pregabalin) Side Effects:
The most commonly reported adverse reactions of LYRICA (Pregabalin) are dizziness and somnolence. Other commonly reported side effects include Appetite increased, Euphoric mood, confusion, libido decreased, irritability, Dizziness, somnolence, Vision blurred, diplopia, Vertigo, Dry mouth, constipation, vomiting, flatulence, fatigue, oedema peripheral, feeling drunk, oedema, gait abnormal. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medications. Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication. There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions. Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance. Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance. Multiple oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone. Pregabalin may potentiate the effects of ethanol and lorazepam. No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Lyrica (pregabalin) is an effective, rapidly acting, and safe treatment for generalized anxiety disorder. In short-term treatment, pregabalin does not appear to have the withdrawal symptoms associated with the benzodiazepines. LYRICA (Pregabalin) is a 3-substituted analogue of gamma-amino butyric acid (GABA) and a compound related to the antiepileptic drug gabapentin. LYRICA (Pregabalin) will be indicated as adjunctive therapy for partial seizures in epilepsy, for treatment of neuopathic pain, including diabetic peripheral neuropathy, and for treatment of generalised anxiety disorder. LYRICA (Pregabalin) is binds to calcium channels and modulates calcium influx as well as influencing GABergic neurotransmission. This mode of action translates into anti-epileptic, analgesic and anxiolytic effects. Because it is more potent than its predacessor Neurontin (gabapentin), Lyrica (Pregabalin) achieves efficacy at lower doses. This increases its therapeutic index with respect to gabapentin and should lead to fewer dose-related side effects. List of excipients include: Capsule content:Lactose monohydrate, Maize starch, Talc, Capsule shell: Gelatin, Titanium Dioxide (E171), Sodium Laurilsulfate, Silica, colloidal anhydrous, purified water. Doses available 75mg, 100 mg, 200 mg and 300 mg shells only: Red Iron Oxide (E172), Printing Ink : Shellac, Black Iron Oxide, (E172), Propylene Glycol, Potassium Hydroxide.
This is interesting point! Claims that Pfizer, the leading drug producers in the world, both over the counter and prescribed drugs, has come up with Lyrica because Neurontin is now 7 years old and that allowed other companies to make a generic copy of Neurontin, hence the design of Lyrica for their next marketing.
www.pfizer.com/are/invest...4_1231.cfm
LYRICA (Pregabalin) is a 3-substituted analogue of gamma-amino butyric acid (GABA) and a compound related to the antiepileptic drug gabapentin. LYRICA (Pregabalin) will be indicated as adjunctive therapy for partial seizures in epilepsy, for treatment of neuopathic pain, including diabetic peripheral neuropathy, and for treatment of generalized anxiety disorder.
FDA Approves Pfizer's Lyrica(TM) for the Treatment of the Two Most Common Forms of Neuropathic (Nerve) Pain
NEW YORK, Dec. 31 /PRNewswire-FirstCall/ -- Pfizer Inc said today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Lyrica(TM) (pregabalin capsules) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) and postherpetic neuralgia (PHN). Lyrica is the first FDA-approved treatment for both of these neuropathic pain states, which are distinctly different from arthritis or musculoskeletal pain.
Developed by Pfizer, Lyrica has a newly defined mechanism of action. Lyrica will be available to physicians and patients in the near future.
NEW YORK (Reuters Health) - A new drug, Lyrica (pregabalin) is a well-tolerated, effective treatment for pain in the extremities often experienced by people with diabetes, according to a recent report. In addition to reducing the pain, the drug seems to improve sleep
Lyrica (Pregabalin) Information:
LYRICA (Pregabalin) is indicated as a treatment for peripheral neuropathic pain and as an adjunctive therapy for partial seizures in patients with epilepsy. The dose range is 150 to 600 mg per day given in either two or three divided doses. Lyrica is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation. Lyrica may be taken with or without food. Neuropathic Pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.Epilepsy: Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual patient response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week. Discontinuation of pregabalin: In accordance with current clinical practice, if pregabalin has to be discontinued either in neuropathic pain or epilepsy, it is recommended this should be done gradually over a minimum of 1 week. Cliniccal Experience- Neuropathic Pain: Efficacy has been shown in studies in diabetic neuropathy and post herpetic neuralgia. Efficacy has not been studied in other models of neuropathic pain. Pregabalin has been studied in 9 controlled clinical studies of up to 13 weeks with twice a day dosing (BID) and up to 8 weeks with three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar. In clinical trials up to 13 weeks, a reduction in pain was seen by week 1 and was maintained throughout the treatment period. In controlled clinical trials 35% of the pregabalin treated patients and 18% of the patients on placebo had a 50% improvement in pain score. For patients not experiencing somnolence, such an improvement was observed in 33% of patients treated with pregabalin and 18% of patients on placebo. For patients who experienced somnolence the responder rates were 48% on pregabalin and 16% on placebo. Clinical Experience- Epilepsy: Pregabalin has been studied in 3 controlled clinical studies of 12 week duration with either twice a day dosing (BID) or three times a day (TID) dosing. Overall, the safety and efficacy profiles for BID and TID dosing regimens were similar. A reduction in seizure frequency was observed by Week 1. Pregabalin binds to an auxiliary subunit (a2-d protein) of voltage-gated calcium channels in the central nervous system, potently displacing [3H]-gabapentin. Speacial Precatuions Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medications. Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication. There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.
Lyrica (Pregabalin) Side Effects:
The most commonly reported adverse reactions of LYRICA (Pregabalin) are dizziness and somnolence. Other commonly reported side effects include Appetite increased, Euphoric mood, confusion, libido decreased, irritability, Dizziness, somnolence, Vision blurred, diplopia, Vertigo, Dry mouth, constipation, vomiting, flatulence, fatigue, oedema peripheral, feeling drunk, oedema, gait abnormal. Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine. In accordance with current clinical practice, some diabetic patients who gain weight on pregabalin treatment may need to adjust hypoglycaemic medications. Pregabalin treatment has been associated with dizziness and somnolence, which could increase the occurrence of accidental injury (fall) in the elderly population. Therefore, patients should be advised to exercise caution until they are familiar with the potential effects of the medication. There are insufficient data for the withdrawal of concomitant antiepileptic medicinal products, once seizure control with pregabalin in the add-on situation has been reached, in order to reach monotherapy on pregabalin.
Since pregabalin is predominantly excreted unchanged in the urine, undergoes negligible metabolism in humans (<2% of a dose recovered in urine as metabolites), does not inhibit drug metabolism in vitro, and is not bound to plasma proteins, it is unlikely to produce, or be subject to, pharmacokinetic interactions. Accordingly, in in vivo studies no clinically relevant pharmacokinetic interactions were observed between pregabalin and phenytoin, carbamazepine, valproic acid, lamotrigine, gabapentin, lorazepam, oxycodone or ethanol. Population pharmacokinetic analysis indicated that oral antidiabetics, diuretics, insulin, phenobarbital, tiagabine and topiramate had no clinically significant effect on pregabalin clearance. Co-administration of pregabalin with the oral contraceptives norethisterone and/or ethinyl oestradiol does not influence the steady-state pharmacokinetics of either substance. Multiple oral doses of pregabalin co-administered with oxycodone, lorazepam, or ethanol did not result in clinically important effects on respiration. Pregabalin appears to be additive in the impairment of cognitive and gross motor function caused by oxycodone. Pregabalin may potentiate the effects of ethanol and lorazepam. No specific pharmacodynamic interaction studies were conducted in elderly volunteers. Lyrica (pregabalin) is an effective, rapidly acting, and safe treatment for generalized anxiety disorder. In short-term treatment, pregabalin does not appear to have the withdrawal symptoms associated with the benzodiazepines. LYRICA (Pregabalin) is a 3-substituted analogue of gamma-amino butyric acid (GABA) and a compound related to the antiepileptic drug gabapentin. LYRICA (Pregabalin) will be indicated as adjunctive therapy for partial seizures in epilepsy, for treatment of neuopathic pain, including diabetic peripheral neuropathy, and for treatment of generalised anxiety disorder. LYRICA (Pregabalin) is binds to calcium channels and modulates calcium influx as well as influencing GABergic neurotransmission. This mode of action translates into anti-epileptic, analgesic and anxiolytic effects. Because it is more potent than its predacessor Neurontin (gabapentin), Lyrica (Pregabalin) achieves efficacy at lower doses. This increases its therapeutic index with respect to gabapentin and should lead to fewer dose-related side effects. List of excipients include: Capsule content:Lactose monohydrate, Maize starch, Talc, Capsule shell: Gelatin, Titanium Dioxide (E171), Sodium Laurilsulfate, Silica, colloidal anhydrous, purified water. Doses available 75mg, 100 mg, 200 mg and 300 mg shells only: Red Iron Oxide (E172), Printing Ink : Shellac, Black Iron Oxide, (E172), Propylene Glycol, Potassium Hydroxide.
This is interesting point! Claims that Pfizer, the leading drug producers in the world, both over the counter and prescribed drugs, has come up with Lyrica because Neurontin is now 7 years old and that allowed other companies to make a generic copy of Neurontin, hence the design of Lyrica for their next marketing.
Quote:
The Food and Drug Administration cleared Pfizer's (PFE:NYSE - news - research) Lyrica for the treatment of pain associated with diabetes and shingles.
The drug remains under review for treatment of partial seizures related to epilepsy.
The lack of immediate action on epilepsy is a mild setback for Pfizer, which had been counting on Lyrica to provide higher profit-margin sales to help offset the revenue erosion due to the epilepsy drug, Neurontin, being hit by generic competition. Neurontin also is approved for treating nerve pain associated with shingles.
Although Pfizer is suing generic companies over Neurontin, it also is marketing its own generic version of the drug. Neurontin produced $2.24 billion in revenue for the first nine months of 2004, making it Pfizer's fifth-best selling drug.
Pfizer's stock slipped 7 cents to $26.94 on Friday.
The FDA gave conditional approval for Lyrica in early September as an add-on treatment for epilepsy, for nerve pain associated with diabetes and for postherpetic neuralgia, which is nerve pain associated with shingles. The agency also rejected Pfizer's application that Lyrica be approved for patients with generalized anxiety disorder.
At the time, Pfizer declined to comment on what it had to do to secure FDA approval for the various uses of the drug.
Once a drug is approved by the FDA for a single disease or condition, doctors may prescribe it for any ailment. However, companies can only market a drug for the uses approved by the FDA.
Pfizer offered no comment Friday on the prospects for Lyrica being approved by the FDA for epilepsy or for general anxiety disorder. The company said Lyrica will be available to doctors and patients "in the near future."
The European Commission approved Lyrica in July for the treatment of peripheral neuropathic pain and as an add-on for partial seizures in patients with epilepsy. Neuropathic pain, or nerve pain, causes burning and tingling sensations.
Analysts have said that clinical trials show Lyrica is superior to Neurontin because it can treat a greater range of diseases, is more potent, requires fewer doses per day and has a better safety profile.
Unlike Neurontin, however, Lyrica will be classified as a controlled substance requiring restrictions for its use. "We view this is a modest disappointment," said Carl Seiden, of UBS, in a Friday report to clients. "With negotiations with the Drug Enforcement Administration ongoing to determine final language on scheduling, the commercial impact remains uncertain."
www.pfizer.com/are/invest...4_1231.cfm
but I
think it was Lyrica that Monica/Mokris was trying out and
doing quite well on.
She
is just in the middle of some music rehearcles before a
big consert, and is so upset.
USA
